Zanzalintinib (also known as XL092) is an inhibitor of several receptor tyrosine kinases, including VEGFR2, MET, and the TAM kinases AXL and MERTK. It could potentially be used to treat colorectal cancer and renal cell carcinoma (RCC).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.